Novel mouse model may help to develop treatment for neurobrucellosis

Neurobrucellosis is a severe long-term complication of brucellosis, one of the most common bacterial zoonotic diseases. Scientists have now developed a novel animal model that indicates that innate lymphoid cells and interferons play an important role in limiting arthritis, meningitis, and neurologic complications during Brucellamelitensis infection. According to a new report 新しいタブ／ウィンドウで開く in The American Journal of Pathology 新しいタブ／ウィンドウで開く, published by Elsevier, this may help understand how neurobrucellosis develops and consequently help explore potential therapies.

Brucellosis is one of the most common bacterial zoonotic diseases in the world, causing significant agricultural and public health problems especially in endemic areas such as the Mediterranean Basin, Middle East, and Central Asia. In animals, it presents as late-term abortion in affected livestock species and causes devastating financial losses. In humans, it can infect and cause disease in almost any organ or organ system. High rates of human disease correlate with lambing season in endemic countries because the disease is transmitted to humans through the ingestion of unpasteurized dairy products or through direct contact (ingestion, inhalation, and wound infection) with contaminated tissues. Brucellosis accounts for more than 500,000 recorded human cases per year, but many believe the actual number of annual infections is 10 to 20 times higher because most cases go undiagnosed.

Lead investigator Jerod A. Skyberg, PhD, Department of Veterinary Pathobiology, College of Veterinary Medicine and Laboratory for Infectious Disease Research, University of Missouri, Columbia, explains: “The disease in humans is characterized by an undulating fever and systemic symptoms, including lethargy, chills, arthralgia, and headaches. The most morbid complication is neurobrucellosis, in which neural tissue is damaged either directly through bacterial disruption or indirectly via severe immune inflammatory responses. The most severely affected patients can develop life-long neurologic consequences.”

The researchers found that innate lymphoid cells and interferons play an important role in defense against central nervous system infection by Brucella and in doing so, have developed novel mouse models for neurobrucellosis to study this further.

Investigators studied the role of innate lymphoid cells (ILCs) and interferons in the pathogenesis of focal brucellosis. After performing footpad infections with Brucella to induce arthritis in mice, they switched to an intranasal infection route to mimic a natural route of infection more closely. In the course of these studies, they observed neurologic signs in mice lacking ILCs and interferons.

ILCs limited articular complications of brucellosis, regardless of the route of infection. In addition, mice lacking ILCs developed neurologic complications of brucellosis including meningitis and colonization of the brain by Brucella. Brucella infection caused a marked upregulation of genes associated with interferon responses and a downregulation of genes associated with neurologic function in the brains of infected mice. Mice lacking interferon signaling also rapidly developed clinical signs of neurobrucellosis and exhibited hippocampal neuronal loss.

Caption: Innate lymphoid cells prevent development of meningitis following pulmonary infection. Rag2^−/−/Il2rg^−/− mice were infected intranasally with 10⁵ colony-forming units of Brucella melitensis. At the development of neurologic complications, or at the conclusion of the study (70 days after infection), brains were collected and transversely sectioned for histopathology. A: Slides were stained with hematoxylin and eosin, and representative images [4× objective (left panels) and 10× objective (right panels)] of naïve and infected sections from the caudal cerebral cortex are shown. The arrows indicate lesions of inflammatory cell infiltrate, and the circle indicates perivascular cuffing. B and C: Immunohistochemistry was performed on serial sections to detect myeloperoxidase (MPO; B) or Brucella antigen (C). B and C: Representative images (10× objective) of rostral cerebrum (left panels), cerebellum (middle panels), and caudal cerebrum (right panels) indicate infiltration of MPO-positive cells (B) and Brucella (C) into the meninges. n = 10 Rag2^−/−/Il2rg^−/− mice (A–C) (Credit: Dr. Charles Moley).

Lead author Charles R. Moley, DVM, Department of Veterinary Pathobiology, College of Veterinary Medicine and Laboratory for Infectious Disease Research, University of Missouri, Columbia notes: “Prior to these observations there had been no experimental animal model for neurobrucellosis, so seeing these signs develop was quite exciting. We were also hoping to be able to visualize the bacteria within the brain via immunohistochemistry; however, we were surprised at the extent of Brucella antigen within the meninges and ventricles of the infected mice. In addition, while type I interferon signaling had previously been reported to be deleterious to control of Brucella infection, here we found that type I interferon signaling limited both colonization of the brain and neuronal loss in response to Brucella infection.”

Collectively, these findings indicate ILCs and interferons play an important role in limiting both arthritis and meningitis during Brucella infection. In addition, this work details the first mouse models of neurobrucellosis in which Brucella colonizes the brain, induces inflammation, and impairs neurologic function. The investigators observe that these models could be used to investigate multiple aspects of neurobrucellosis such as invasion of the brain by Brucella or therapeutics for treatment of neurologic complications of brucellosis.

Dr. Skyberg and Dr. Moley conclude: “Considering that neurobrucellosis is the most morbid complication caused by this bacterium, learning more about its development, effects on the immune system, and potential therapies to counteract damage to the host central nervous system may benefit patients worldwide.”

---

Notes for editors

The article is “Innate Lymphoid Cells and Interferons Limit Neurologic and Articular Complications of Brucellosis,” by Charles R. Moley, Catherine A. Chambers, Alexis S. Dadelahi, Bárbara Ponzilacqua-Silva, Mostafa F.N. Abushahba, Carolyn A. Lacey, Craig L. Franklin, and Jerod A. Skyberg (https://doi.org/10.1016/j.ajpath.2023.05.006 新しいタブ／ウィンドウで開く). It appears online in advance of The American Journal of Pathology, volume 193, issue 9 (September 2023), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(23)00198-0/fulltext 新しいタブ／ウィンドウで開く.

The study was supported by NIH grants R21AI153074, R01AI150797, and OD011126-44.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 238 3628 or [email protected] 新しいタブ／ウィンドウで開く to request a PDF of the article. To request an interview with the authors please contact Jerod Skyberg, PhD, at [email protected] 新しいタブ／ウィンドウで開く.

About The American Journal of Pathology

The American Journal of Pathology 新しいタブ／ウィンドウで開く, official journal of the American Society for Investigative Pathology 新しいタブ／ウィンドウで開く, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. https://ajp.amjpathol.org 新しいタブ／ウィンドウで開く

エルゼビアについて

エルゼビアは情報分析を専門としたグローバル企業として、研究者や医療専門家の方々を支援し、社会にとっての利益最大化に向けて、科学や医療の進展を支えています。これは、信頼できるエビデンスによるコンテンツと高度なAI対応によるデジタル技術に基づく革新的なソリューションにより、知見の集積や重要な意思決定を支援することで実現されています。

エルゼビアは、全世界で9,700人の従業員（うち技術者2,300人以上）を抱え、140年以上にわたって、研究者、図書館員、アカデミックリーダー、資金提供者、政府、研究開発集約型企業、医師、看護師、将来の医療専門家、教育者など研究・医療分野におけるパートナーの重要な活動を支援してきました。エルゼビアが刊行する3,000誌以上の科学ジャーナルと代表的な参考書には、The Lancet 新しいタブ／ウィンドウで開く、Cell Press 新しいタブ／ウィンドウで開くおよびGray’s Anatomyなどをはじめとする、各分野を代表する主要なタイトルが含まれています。 エルゼビア・ファンデーション 新しいタブ／ウィンドウで開くとの活動を通し、私たちがサービスを提供する地域社会と連携して、開発途上国を含む世界中の医学、研究、医療分野における、インクルージョン＆ダイバーシティ（I&D）の改善に努めています。

エルゼビアは、専門家および企業向けの情報分析および意思決定ツールのグローバルプロバイダーであるRELX Group 新しいタブ／ウィンドウで開くの一事業を担っています。エルゼビアの事業内容、デジタルソリューション、コンテンツなどの詳細については、www.elsevier.comをご覧ください。